Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia first-in-human single-center, randomized, double-blind, placebo-controlled, single ascending dose study of RZ402 for Diabetic Macular Edema

Next Previous
Trial Profile

A Phase Ia first-in-human single-center, randomized, double-blind, placebo-controlled, single ascending dose study of RZ402 for Diabetic Macular Edema

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RZ 402 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; First in man
  • Sponsors Rezolute

Most Recent Events

  • 04 May 2021 Status changed from recruiting to active, no longer recruiting, according to a Rezolute media release.
  • 04 May 2021 Topline results published in the Rezolute media release.
  • 12 Jan 2021 According to a Rezolute media release, the company expect to complete the study in the first half of 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top